Lai SL - Search Results

1

Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.

Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, Lee SD. Huang YS, et al. Among authors: lai sl. Hepatology. 2002 Apr;35(4):883-9. doi: 10.1053/jhep.2002.32102. Hepatology. 2002. PMID: 11915035

2

Latent TB infection in newly diagnosed lung cancer patients - A multicenter prospective observational study.

Fan WC, Ting WY, Lee MC, Huang SF, Chiu CH, Lai SL, Chen YM, Shih JF, Lin CH, Kao SJ, Wu MF, Tsao TC, Wu CH, Yang KY, Lee YC, Feng JY, Su WJ. Fan WC, et al. Among authors: lai sl. Lung Cancer. 2014 Sep;85(3):472-8. doi: 10.1016/j.lungcan.2014.07.001. Epub 2014 Jul 9. Lung Cancer. 2014. PMID: 25063540

3

Amyloidosis and the risk of cancer: a nationwide population-based study.

Su VY, Liu CJ, Hu YW, Su WJ, Chen YM, Lai SL, Chen TJ, Perng DW, Lee YC, Tzeng CH, Chou KT. Su VY, et al. Among authors: lai sl. Int J Clin Oncol. 2015 Dec;20(6):1244-51. doi: 10.1007/s10147-015-0849-9. Epub 2015 Jun 4. Int J Clin Oncol. 2015. PMID: 26041464

4

Combination versus alternating chemotherapy in small-cell lung cancer.

Lai SL, Perng RP. Lai SL, et al. Zhonghua Yi Xue Za Zhi (Taipei). 2000 Jul;63(7):513-20. Zhonghua Yi Xue Za Zhi (Taipei). 2000. PMID: 10934803 Clinical Trial.

5

Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations.

Wu WS, Chen YM, Tsai CM, Shih JF, Chiu CH, Chou KT, Lai SL, Wu CH, Luo YH, Huang CY, Lee YC, Perng RP, Whang-Peng J. Wu WS, et al. Among authors: lai sl. Exp Ther Med. 2012 Feb;3(2):207-213. doi: 10.3892/etm.2011.383. Epub 2011 Nov 16. Exp Ther Med. 2012. PMID: 22969870 Free PMC article.

6

Impact of nutritional status on the survival of lung cancer patients.

Lai SL, Perng RP. Lai SL, et al. Zhonghua Yi Xue Za Zhi (Taipei). 1998 Mar;61(3):134-40. Zhonghua Yi Xue Za Zhi (Taipei). 1998. PMID: 9556944

7

p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells.

Lai SL, Perng RP, Hwang J. Lai SL, et al. J Biomed Sci. 2000 Jan-Feb;7(1):64-70. doi: 10.1007/BF02255920. J Biomed Sci. 2000. PMID: 10644891

8

The association between tumor epidermal growth factor receptor (EGFR) mutation and multiple primary malignancies in patients with adenocarcinoma of the lungs.

Luo YH, Ho HL, Tsai CM, Shih JF, Chiu CH, Lai SL, Lee YC, Perng RP, Whang-Peng J, Chou TY, Chen YM. Luo YH, et al. Among authors: lai sl. Am J Clin Oncol. 2015 Apr;38(2):147-51. doi: 10.1097/COC.0b013e318292f88c. Am J Clin Oncol. 2015. PMID: 23608835

9

Erlotinib Salvage Therapy in Pulmonary Adenocarcinoma Patients With Disease Progression After Previous EGFR-TKI Treatment.

Wu WS, Wu CH, Lai SL, Chiu CH, Shih JF, Lee YC, Chen YM. Wu WS, et al. Among authors: lai sl. Am J Clin Oncol. 2016 Dec;39(6):556-562. doi: 10.1097/COC.0000000000000096. Am J Clin Oncol. 2016. PMID: 24937633

10

Sialyl stage-specific embryonic antigen-1: a useful marker for differentiating the etiology of pleural effusion.

Lee YC, Chern JH, Lai SL, Perng RP. Lee YC, et al. Among authors: lai sl. Chest. 1998 Dec;114(6):1542-5. doi: 10.1378/chest.114.6.1542. Chest. 1998. PMID: 9872185

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

229 results

Search Page

Filters